Novo Nordisk To Build $4.1-Bn Fill-Finish Mfg Facility in North Carolina

Novo Nordisk has announced plans to invest $4.1 billion to build a second fill–finish manufacturing facility in Clayton, North Carolina, to support production for current and future injectable products for treating obesity and other serious chronic diseases. 

Marking one of the largest manufacturing investments in Novo Nordisk’s history, the expansion will add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, doubling the combined square footage of all three of the company’s existing facilities in North Carolina. Early clearing and foundational work are already underway to prepare the 56-acre facility footprint. Construction will gradually be finalized between 2027 and 2029. 

Overall, in 2024, Novo Nordisk will increase actual investments in production and plans to invest approximately $6.8 billion in production compared to actual investments of $3.9 billion in 2023 to increase supply. Novo Nordisk has a global manufacturing  network with five strategic production sites in Denmark, the US, France, Brazil and China. 

Source: Novo Nordisk